Reprogramming the tumor's
immune context — from the gut up.
Immunotherapy works when the immune system can see the tumor. For a large share of patients, an unfavorable gut microbiome quietly keeps it blind. OBX34 is designed to restore that signal with the precision of a small molecule.
A disrupted microbiome is a hidden driver of immunotherapy failure.
Immunotherapies work by unleashing the immune system on the tumor — but only if the environment around the tumor lets them. The make-up of the gut microbiome is one of the strongest influences on whether it does, and that shows up most clearly with checkpoint inhibitors, the most common immunotherapy.
When the microbiome is disrupted — most often by antibiotics in the weeks before treatment — response rates and survival fall. The pattern holds across melanoma, kidney, and lung cancer, and it is large: pooled studies find roughly a 60% higher risk of death when antibiotics come before immunotherapy.
- Common. About one in five patients begins immunotherapy having recently taken antibiotics — identifiable from prescribing records alone.
- Consequential. These patients do meaningfully worse on the same therapy as everyone else.
- Fixable. The disruption is chemical — which means, in principle, a drug can correct it.
Fecal transplant from responders converted previously refractory melanoma patients into responders.
Two independent 2021 Science trials showed that changing the microbiome changes outcomes in patients — the first direct human evidence that this is cause, not just correlation.
Synthetic microbiome mimetics: the biology of a healthy gut, without the organisms.
What the microbiome does for the immune system is, at its core, chemistry. Those active signals can be identified, made in a lab, and given as ordinary, well-understood drugs — keeping the benefit while shedding everything that makes living treatments hard to develop. It's an emerging class of medicine, and Oncobiotix is helping define it.
Demonstrated in people — but a stool transplant is challenging and costly to mass-produce, standardize, and combine with other drugs. It isn't yet a medicine.
More consistent than a transplant, but they rely on living microbes taking hold in the gut — hardest in the very patients who just had antibiotics.
Consistent chemistry, a clear dose, stable at room temperature, and an ordinary regulatory path. The same signal — in a pill.
One defined switch: the Gasdermin D / IL-1β pathway inside the tumor's immune cells.
Solid tumors are crowded with immune cells (myeloid cells) that suppress the attack. OBX34 turns up one specific danger signal inside them — amplifying a mechanism that's already there, rather than introducing a foreign one. Because it acts on the tumor's environment instead of targeting any single drug's pathway, the same approach should help immunotherapy broadly — and we will test it first where the human evidence is strongest: checkpoint immunotherapy in lung cancer.
Oral, microbiome-independent
OBX34 reaches tumor-associated myeloid cells directly — it does not require the patient to have a favorable microbiome of their own.
Selective enhancement
It enhances canonical inflammasome assembly and caspase-mediated cleavage of Gasdermin D — a controlled amplification of an existing signal.
N-GSDMD → membrane pore
Cleaved N-terminal GSDMD oligomerizes into a membrane pore, enabling the export of mature IL-1β.
IL-1β → CD8⁺ expansion
Secreted IL-1β drives CD8⁺ T-cell expansion and anti-tumor activity — restoring responsiveness to immunotherapy.
In preclinical tumor models, adding OBX34 to PD-1 immunotherapy improved survival — including when the gut microbiome was disrupted by antibiotics.
It improved the response
Adding OBX34 to PD-1 immunotherapy in a preclinical tumor model took long-term survival from about a quarter to about three quarters — well beyond either treatment on its own.
It rescued a disrupted gut
In preclinical models, antibiotics cut the benefit of PD-1 immunotherapy by two thirds. Adding OBX34 on top of the antibiotics restored it — past what immunotherapy achieved with an undisturbed gut.
Both panels show measured preclinical survival data, redrawn from Sikdar et al., bioRxiv 2026 (preprint, not yet peer reviewed). The full supporting data package is available on request.
The full mechanism, data package, and clinical plan.
See how OBX34 moves from mechanism to first-in-human, or review the literature the approach is built on.